Personalized Therapy for Basic and Translational in Upper Gastrointestinal Cancer

Dear Colleagues,

Upper gastrointestinal cancer, encompassing gastroesophageal, pancreatic and hepatobiliary tract cancer, is one of the most common cancers worldwide, with high morbidity and mortality. Gastrointestinal cancers are characterized by enormous heterogeneity, even with the presence of many mutations in multiple tumor entities. In recent years, from the beginning of diagnosis to the development of new surgical techniques to the most innovative medical therapies, the treatment of these tumors has changed profoundly. Furthermore, today's developments in translational oncology allow for personalized treatments based on molecular profiling and genetic tools. Interestingly, an emerging key role of microbiota both in carcinogenesis and treatment response has been highlighted in the last few years.

Evolving strategies for early cancer detection and treatment have improved overall survival. Gastrointestinal cancer surgeries, such as laparoscopy and robotic resection, are still effective treatments. In addition to traditional chemotherapy, targeted therapy and immunotherapy have further improved the treatment and survival rate of patients with upper gastrointestinal cancer, providing new opportunities for personalized cancer treatment.

For this Special Issue, we invite submissions of the latest original research and comprehensive reviews about all aspects of basic and translational upper gastrointestinal cancer treatment.

Dr. Valeria Merz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.